Cefixime Capsules
Ingredients
The main ingredient of this product is cefixime
Molecular formula:
C16H15N5O7S2·3H2O
Molecular weight: 507.50
character
The content of this product is white or light yellow powder.
indication
This product is suitable for the following bacterial infectious diseases, such as Streptococcus (except Enterococcus), pneumococcus, Neisseria gonorrhoeae, hantavirus catarrhalis, Escherichia coli, Klebsiella, Serratia, Proteus and influenza, which are sensitive to cefixime
1. Bronchitis, bronchiectasis (infection), secondary infection of chronic respiratory infection, pneumonia;
2. Pyelonephritis, cystitis and gonococcal urethritis;
3. Cholecystitis, cholangitis;
4. Scarlet fever;
5. Otitis media, paranasal sinusitis.
Usage and dosage
Dosage for adults and children weighing more than 30 kg: oral, 0.1 g (1 capsule), twice a day; in addition, it can be increased or decreased according to age, weight and symptoms, for severe patients, it can be 0.2 g (2 capsules), twice a day.
Adverse reactions
Clinical research data showed that the main adverse reactions of this product were diarrhea and other gastrointestinal reactions (0.87%), skin rash and other skin symptoms (0.23%), abnormal clinical examination values (including elevated GPT (0.61%), elevated got (0.45%), and eosinophilia (0.20%). The details are as follows:
Serious adverse reactions were observed
(1) Shock: the possibility of shock (< 0.1%) should be observed closely. In case of discomfort, abnormal feeling in mouth, asthma, dizziness, defecation, tinnitus, sweating and other phenomena, the administration should be stopped and appropriate measures should be taken.
(2) Allergic symptoms: the possibility of allergic symptoms (including dyspnea, systemic flushing, angioneurotic edema, urticaria, etc.) (< 0.1%) should be closely observed. If there is any abnormality, stop the administration and take appropriate measures.
(3) Skin lesions: the possibility of skin and mucous membrane ophthalmic syndrome (Stevens Johnson syndrome (0.1%) and toxic epidermal necrosis (Lyell syndrome, < 0.1%) should be closely observed. In case of fever, headache, joint pain, skin or mucous erythema, blisters, skin tension, burning sensation, pain and other symptoms, the administration should be stopped and appropriate treatment should be taken.
(4) Blood disorders: the possibility of agranulocytosis (< 0.1%, early symptoms: fever, sore throat, headache, burnout, etc.), hemolytic anemia (< 0.1%, early symptoms: fever, hemoglobinuria, anemia, etc.), thrombocytopenia (< 0.1%, early symptoms: punctate hemorrhage, purple spot, etc.) and the same as other cephalosporins The report of pancytopenia should be closely observed, such as regular examination. When there is any abnormality, the administration should be stopped and appropriate treatment should be taken.
(5) Renal dysfunction: there is the possibility of causing severe renal dysfunction (< 0.1%) such as acute renal insufficiency. Therefore, close observation should be carried out, such as regular examination. If there is any abnormality, the administration should be stopped and appropriate treatment should be taken.
(6) Colitis: may cause severe colitis with bloody stool, such as pseudomembranous colitis (< 0.1%). In case of abdominal pain and recurrent diarrhea, the administration should be stopped immediately and appropriate treatment should be taken.
(7) Interstitial pneumonia (with fever, cough, dyspnea, chest X-ray abnormalities, eosinophilia and other symptoms) and pie syndrome (all < 0.1%) are likely to occur. If the above symptoms occur, the drug should be stopped, and appropriate treatment such as glucocorticoid should be taken.
taboo
It is forbidden to be allergic to this product and its ingredients or other cephalosporins.
matters needing attention
1. Due to the possibility of shock, the medical history should be fully inquired before administration.
2. In order to prevent the emergence of drug-resistant strains, the sensitivity should be confirmed in principle before using this product, and the dose should be controlled at the minimum dose required for disease control.
3. For patients with severe renal dysfunction, because the drug concentration can be maintained in the blood, it should be reduced according to the renal function, and the interval of administration should be increased. (refer to [pharmacokinetic data]).
4. The following patients were treated with caution:
(1) Patients with history of allergy to penicillins;
(2) I or parents, brothers, with easy to cause bronchial asthma, rash, urticaria and other allergic symptoms of patients with physical constitution.
(3) Patients with severe renal dysfunction (refer to [pharmacokinetic data]).
(4) Patients with oral administration difficulties or non oral intake of nutrition, patients with systemic cachexia (due to vitamin K deficiency symptoms, attention should be paid to observation).
5. Influence on clinical test results:
(1) When using Benedict reagent, Fehling reagent and clinitest to test the urine sugar, we should pay attention to the possibility of false positive.
(2) We should pay attention to the possibility of false positive of direct Coombs test.
6. Do not mix milk, juice, etc. with medicine and place them.
7. Others:
In the experiment of young rats, oral administration of more than 1000 mg / kg can inhibit spermatogenesis.
| Cephalosporin Antibacterial |
Specifications |
| Cefadroxil Capsules |
250mg, 500mg |
| Cefadroxil Tablets |
250mg, 500mg |
| Cefalexin Capsules |
125mg, 250mg, 500mg |
| Cefixime Tablets |
100mg, 200mg, 400mg |
| Cefixime Dispersible Tablets |
100mg, 200mg, 400mg |
| Cefixime Capsules |
100mg, 200mg, 400mg |
| Cefixime Granules |
100mg, 200mg, 400mg |
| Cefuroxime Axetil Tablets |
125mg, 250mg, 500mg |
| Cefradine Capsules |
250mg, 500mg |
| Cefradine Tablets |
250mg, 500mg |
| Cefotiam Hexetil Hydrochloride Tablets |
100mg, 200mg |
Audited Supplier 
){kind=link}